The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.

The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.

The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.

The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.

The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.

The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.

The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.

The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics (NASDAQ: ACER) was provided by HC Wainwright & Co., and Acer Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics (ACER) is trading at is $0.83, which is out of the analyst’s predicted range.